Coverage Initiated: March 2010
Coverage Terminated: August 2011

Cell Therapeutics (CTIC) has spent over $1.4B of shareholder money with nothing to show for it. If you ask biotech experts for a lsit of the worst publicly-traded biotech companies, CTI ends up on everyone's list.

CTI was the first company we initiated bearish coverage on. The story is such a drumbeat of negativity, however, we were always writing the same thing. We terminated coverage in August 2011 because we felt our efforts were better spent finding companies where the investment case wasn't always the same.

A complete listing of our research on Cell Therapeutics is available by clicking here.